Author: digi

Building SOPs for Lab Result Interpretation and Query Resolution

October 9, 2025

Building SOPs for Lab Result Interpretation and Query Resolution Creating Robust SOPs for Lab Result Interpretation and Query Resolution in Clinical Trials Introduction: The Need for Structured Lab Data Handling Laboratory results form the foundation of many safety and efficacy endpoints in clinical trials. Inadequate interpretation of lab values or delayed response to data queries…

Central vs Local Labs, Laboratory and Sample Management

SOP for Telemedicine Visits and Remote AE Reporting

October 9, 2025

digi

SOP for Telemedicine Visits and Remote AE Reporting { “@context”: “https://schema.org”, “@type”: “Article”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://www.clinicalstudies.in/sop-for-telemedicine-visits-and-remote-ae-reporting” }, “headline”: “SOP for Telemedicine Visits and Remote AE Reporting”, “description”: “This SOP describes standardized procedures for conducting telemedicine visits and remote adverse event (AE) reporting in clinical trials. It ensures compliance with FDA, EMA, CDSCO,…

SOP for GCP, SOP for IDE/Device

EU Trials Involving Medical Devices Under MDR/IVDR

October 9, 2025

digi

EU Trials Involving Medical Devices Under MDR/IVDR Clinical Trials of Medical Devices in the EU: Navigating MDR and IVDR Requirements The European Union (EU) has transformed its regulatory landscape for medical devices and in vitro diagnostics with the introduction of the Medical Device Regulation (MDR, Regulation (EU) 2017/745) and the In Vitro Diagnostic Regulation (IVDR,…

Clinical Trials in EU, Country-Specific Clinical Trials

Overview of Canadian Clinical Trial Regulation and Governance

October 9, 2025

digi

Overview of Canadian Clinical Trial Regulation and Governance Canadian Clinical Trial Regulation: A Comprehensive Overview Canada has established itself as a leading hub for clinical research, offering a robust regulatory framework, world-class academic institutions, and a diverse patient population. Clinical trials in Canada are regulated primarily by Health Canada under the Food and Drugs Act…

Clinical Trials in Canada, Country-Specific Clinical Trials

Rare Disease Trials in China: Regulatory Pathways

October 9, 2025

digi

Rare Disease Trials in China: Regulatory Pathways Regulatory Pathways for Rare Disease Clinical Trials in China Introduction Rare diseases affect an estimated 20 million people in China, yet historically these patients had limited access to innovative therapies. Clinical trials for rare diseases face unique challenges, including small patient populations, recruitment barriers, and limited disease registries….

Clinical Trials in China, Country-Specific Clinical Trials

Data Flow Control During Adaptive Modifications

October 9, 2025

digi

Data Flow Control During Adaptive Modifications Managing Data Flow During Adaptive Modifications in Clinical Trials Introduction: Why Data Flow Matters in Adaptive Designs Adaptive clinical trial designs require interim analyses to guide modifications such as sample size re-estimation, arm dropping, or eligibility adjustments. These adaptations depend on data flow control—the management of when, how, and…

Adaptive Modifications Based on Interim Data, Interim Analysis and Trial Termination

Compliance Playbook – Protocol-Driven Lab Selection

October 9, 2025

digi

Compliance Playbook – Protocol-Driven Lab Selection Aligning Lab Selection with Clinical Protocol Requirements: A Regulatory Playbook Introduction: The Importance of Protocol-Driven Lab Strategy In clinical trials, the selection of a central or local laboratory is rarely arbitrary. It must be driven by the clinical protocol’s scientific, logistical, and regulatory requirements. A mismatch between lab capability…

Central vs Local Labs, Laboratory and Sample Management

EMA’s Approach to Biomarker-Based Trials

October 9, 2025

digi

EMA’s Approach to Biomarker-Based Trials How EMA Regulates and Supports Biomarker-Based Clinical Trials Biomarker-based clinical trials are transforming drug development by enabling precision medicine, patient stratification, and improved therapeutic outcomes. In the European Union (EU), the European Medicines Agency (EMA) plays a pivotal role in guiding the design, validation, and regulatory acceptance of biomarkers in…

Clinical Trials in EU, Country-Specific Clinical Trials

Documenting Due Diligence for Audits

October 9, 2025

digi

Documenting Due Diligence for Audits Comprehensive Guide to Documenting Due Diligence for Clinical Trial Audits Introduction: Why Documentation Defines Oversight Quality In the increasingly outsourced landscape of clinical research, vendor qualification and oversight have become core elements of sponsor responsibility. However, the effectiveness of vendor oversight does not end with conducting audits or risk assessments—it…

Due Diligence and Risk Assessment, Outsourcing and Vendor Management

Impact of Data Localization Laws on Multinational Trials in China

October 9, 2025

digi

Impact of Data Localization Laws on Multinational Trials in China How Data Localization Laws Shape Multinational Clinical Trials in China Introduction China’s data localization laws are reshaping the way multinational sponsors design and execute clinical trials in the country. Under the Cybersecurity Law (2017), the Data Security Law (2021), and the Personal Information Protection Law…

Clinical Trials in China, Country-Specific Clinical Trials